Language:

ACCELERATE - Five years accelerating cancer drug development for children and adolescents

European journal of cancer (1990), 2022-05, Vol.166, p.145-164 [Peer Reviewed Journal]

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. ;Attribution - NonCommercial - NoDerivatives ;ISSN: 0959-8049 ;EISSN: 1879-0852 ;DOI: 10.1016/j.ejca.2022.01.033 ;PMID: 35290915

Digital Resources/Online E-Resources

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
ACCELERATE - Five years accelerating cancer drug development for children and adolescents
Author: Pearson, Andrew D J ; Weiner, Susan L ; Adamson, Peter C ; Karres, Dominik ; Reaman, Gregory ; Rousseau, Raphaël ; Blanc, Patricia ; Norga, Koen ; Skolnik, Jeffrey ; Kearns, Pam ; Scobie, Nicole ; Barry, Elly ; Marshall, Lynley V ; Knox, Leona ; Caron, Hubert ; Wariabharaj, Darshan ; Pappo, Alberto ; DuBois, Steven G ; Gore, Lia ; Kieran, Mark ; Weigel, Brenda ; Fox, Elizabeth ; Nysom, Karsten ; de Rojas, Teresa ; Vassal, Gilles
Subjects: Adolescent ; Adult ; Antineoplastic Agents - adverse effects ; Child ; Drug Development ; Humans ; Life Sciences ; Neoplasms - drug therapy ; United States ; United States Food and Drug Administration
Is Part Of: European journal of cancer (1990), 2022-05, Vol.166, p.145-164
Description: Rapid evaluation and subsequent regulatory approval of new drugs are critical to improving survival and reducing long-term side-effects for children and adolescents with cancer. The international multi-stakeholder organisation ACCELERATE was created to advance the timely investigation of new anti-cancer drugs. ACCELERATE has enhanced communication and understanding between academia, industry, patient advocates and regulators. It has promoted a mechanism-of-action driven drug development approach and developed Paediatric Strategy Forums. These initiatives have facilitated prioritisation of medicinal products and a focused and sequential strategy for drug development where there are multiple potential agents. ACCELERATE has championed the early assessment of promising drugs in adolescents through their inclusion in adult early phase trials. ACCELERATE has strongly supported alignment between the European Medicines Agency and the US Food and Drug Administration and identification of unmet medical needs through multi-stakeholder collaboration. Early engagement between all stakeholders in the development of new drugs is critical. Innovative clinical trial designs are required, necessitating early discussion with sponsors and regulators. Amplifying the patient advocate voice through inclusion across the drug development continuum will lead to better, patient-centric trials. By these means, children and adolescents with cancer can maximally and rapidly benefit from innovative products to improve outcomes and reduce burdensome sequelae.
Publisher: England: Elsevier
Language: English
Identifier: ISSN: 0959-8049
EISSN: 1879-0852
DOI: 10.1016/j.ejca.2022.01.033
PMID: 35290915
Source: Hyper Article en Ligne (HAL) (Open Access)

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

ACCELERATE - Five years accelerating cancer drug development for children and adolescents

Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. ;Attribution - NonCommercial - NoDerivatives ;ISSN: 0959-8049 ;EISSN: 1879-0852 ;DOI: 10.1016/j.ejca.2022.01.033 ;PMID: 35290915

Searching Remote Databases, Please Wait